Life sciences firm Metabolon has added two more patents to its growing intellectual property portfolio.

The company now holds 17 patents in the US.

Metabolon’s technology is based on metabolomics. The venture capital-backed firm has developed technology for the biomarkers through profiling of biochemicals such as sugars, nucleotides, fatty acids, amino acids and other small molecules, the company said. The biochemicals are analyzed in patient samples before being compared to other profiles.

Metabolon believes the data can be used for development of diagnostic tests as well as drug development and in monitoring for clinical trials.

The latest patents are for methods of drug discovery and method for analysis using metabolomics technology.

“These patents support our intellectual property strategy for our biomarker and biochemical analysis program, which will aid in predicting drug responses in individuals and identifying disease biomarkers for more personalized treatment,” said John Ryals, Metabolon’s chief executive officer. “With 17 issued US patents broadly covering metabolomics methods and software, Metabolon has assembled the dominant IP position in the field of metabolomics.”

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.